Researchers at the Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, USA have reported a genetic association between UBAP1L variants and retinal… Read More »A novel IRD candidate gene, UBAP1L, provides a loss-of-function causing macular, cone and cone-rod dystrophy.
Clinical researchers at the Center for Hereditary Retinal Degenerations, Scheie Eye Institute, University of Pennsylvania, Philadelphia, have published the results of a Phase 1/2 study… Read More »Dose escalation study of ASTN-101 (AAV5-GUCY2D) for LCA1 patients provide improvement in FST and BCVA (Phase 1/2).
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Massachusetts, have announced positive interim 16-week data for an ongoing Phase 2 “VERONA” clinical trial, evaluating “DURAVYU”… Read More »EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.
Dear EURETINA Members, A very warm welcome to the October 24th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »October 24th, 2024 “EURETINA-Brief”© Issue No. 302
Researchers at the University of New South Wales, Sydney, Australia, have reported a new study indicating that RPE curvature may provide a promising quantitative outer… Read More »A new research study on RPE curvature may provides a promising quantitative biomarker for late AMD.
An international clinical research consortium has reported recommendations on endpoints and design of clinical trials in USH2A-related retinal degenerations. The study, supported by the US… Read More »Endpoints and clinical trial design for IRDs and USH2A reporting outcomes from a natural history study.
Ocuphire Pharma, Inc. (Nasdaq: OCUP), based in Farmington Hills, Michigan, USA announced the all-stock acquisition of Opus Genetics, Inc., a private ocular gene therapy company… Read More »Ocuphire Pharma Inc., has acquired Opus Genetics, aimed to advance treatments quickly for several ophthalmic indications.
Dear EURETINA Members, A very warm welcome to the October 10th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »October 10th, 2024 “EURETINA-Brief”© Issue No. 301
Researchers at UCL Institute of Ophthalmology, University College London, and Moorfields Eye Hospital NHS Foundation Trust, UK, have reported a study on CNG3A-associated achromatopsia (ACMH),… Read More »CNGA3-associated ACHM displays stable foveal cone structure over time, presenting an attractive therapeutic opportunity for treatment.
EURETINA Congress, Barcelona – Sept. 20th, 2024: Prof. M. Dominick Fischer, based at Nuffield Laboratory of Ophthalmology, University of Oxford and the Oxford Eye Hospital,… Read More »Real world data from the treatment by voretigene neparvovec (Luxturna) of LCA2-RPE65 patients across 24 countries.
